Canada· CA-DIN-02552434
OPZELURA
A ruxolitinib product containing ruxolitinib (ruxolitinib phosphate), registered in Canada by INCYTE CORPORATION. The same ATC class is registered in 14 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Ruxolitinib is registered in 14 of 19 countries.
Countries holding a registration under ATC D11AH09 (ruxolitinib), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Ruxolitinib · ATC D11AH09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- RUXOLITINIB (RUXOLITINIB PHOSPHATE)
- Manufacturer
- INCYTE CORPORATION
- Country
- Canada (CA)
- ATC code
- D11AH09
- ATC class
- Ruxolitinib
- Defined daily dose
- 30 mg, T
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ruxolitinib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaJAKAVINovartis Europharm Limited, Dublin
- NetherlandsJakavi 10 mg, tabletNovartis Europharm Limited
- SwedenJakavi 10 mg TablettNovartis Europharm Limited
- SwitzerlandJakavi
- IcelandJakaviNovartis Europharm Limited*
- United StatesJAKAFIIncyte Corporation
- FinlandJakaviNovartis Europharm Limited
- SpainJAKAVI 10 MG COMPRIMIDOSNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 23 EEA countries. Names it is sold under:
- Austria · Polink, Ruxib
- Bulgaria · Руджави, Руксолитиниб Сандоз
- Cyprus · Ruxolitinib Sandoz
- Czechia · Ruxolitinib Msn, Ruxolitinib Sandoz
- Denmark · Ruxolitinib "sandoz", Ruxolitinib Devatis
- Estonia · Ruxolitinib Msn
- Spain · Ruxolitinib Cipla, Ruxolitinib Vivanta
- Finland · Ruxolitinib Orion
- France · Ruxolitinib Biogaran, Ruxolitinib Olpha
- United Kingdom (Northern Ireland) · Ruxolitinib Msn Laboratories Europe, Ruxolitinib Torrent
- Greece · Jakulya
- Croatia · Ruksolitinib Devatis, Ruksolitinib Msn
- Hungary · Ruxolitinib Sandoz
- Iceland · Jakavi, Jakulya
- Italy · Ruxolitinib Vivanta
- Liechtenstein · Jakavi, Opzelura
- Lithuania · Ruxolitinib Msn, Ruxolitinib Olpha
- Latvia · Ruxolitinib Msn
- Malta · Donlize, Ruxolitinib Medichem
- Netherlands · Ruxolitinib Accord, Ruxolitinib Advanz Pharma
- Norway · Jakavi, Opzelura
- Romania · Ruxolitinib Msn
- Sweden · Ruxolitinib Devatis, Ruxolitinib Orion
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f5291df7-d2ef-4b1d-b730-db57e53dbd8b GET /v1/drugs/f5291df7-d2ef-4b1d-b730-db57e53dbd8b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02552434",
"form": "CREAM",
"class": "Human",
"routes": [
"TOPICAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "D11AH09",
"schedule": [
"Prescription"
],
"drug_code": "104109",
"strengths": [
"1.5 %"
],
"ahfs_class": null,
"substances": [
"RUXOLITINIB (RUXOLITINIB PHOSPHATE)"
],
"product_categorization": null
}See everything about ruxolitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.